LFA-1 Radioligand Imaging for Atherosclerotic Plaque Vulnerability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic tools for atherosclerosis are limited in their ability to detect early stages of the disease, leading to late-stage symptoms and increased risk of cardiovascular events, and they lack specificity in identifying intraplaque leukocyte subtypes, which are crucial for assessing plaque vulnerability.
Innovation Solution
A novel radioligand, DANBIRT, targeted at leukocyte function-associated antigen-1 (LFA-1), is developed, which can be labeled with radioisotopes like 111In for non-invasive imaging of inflammation and immune cell activity in vascular tissues, allowing for the detection of atherosclerotic plaque vulnerability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic tools are used for atherosclerosis detection, then the diagnostic process is simple and non-invasive, but the detection precision is insufficient for early-stage disease and intraplaque leukocyte subtypes
Solution Approach 1:
The patent introduces radiolabeled imaging agents as intermediaries that specifically bind to leukocyte subtypes within atherosclerotic plaques. These agents serve as mediators between the imaging system and the target cells, enabling precise detection of intraplaque inflammation without requiring direct visualization of the plaque structure itself.
Solution Approach 2:
The patent employs multiple radiolabeled agents with different molecular targets and binding specificities to detect various leukocyte subtypes. By changing the molecular parameters of the imaging agents (different ligands, radiolabels, and target molecules), the system achieves enhanced detection precision for early-stage atherosclerosis and specific plaque vulnerability markers.
2Measurement precision
If invasive methods are used to identify intraplaque leukocyte subtypes, then measurement precision improves, but ease of operation deteriorates
Solution Approach 1:
The radiolabeled imaging agents act as intermediaries that can be administered systemically and accumulate specifically at the plaque site, binding to leukocyte subtypes without requiring direct access to the plaque. This eliminates the need for invasive procedures while maintaining high detection precision through the selective binding properties of the imaging agents.
Solution Approach 2:
The patent replaces mechanical/invasive biopsy methods with a molecular imaging approach using radiolabeled agents. Instead of physically extracting and analyzing plaque tissue, the system uses radioactive tracers that bind to specific leukocyte markers, allowing non-invasive detection of intraplaque inflammation through external imaging scanners.
3Reliability
If late-stage diagnosis is performed, then device complexity remains low, but reliability of cardiovascular event prevention deteriorates
Solution Approach 1:
The patent enables preliminary detection of atherosclerotic plaques and intraplaque inflammation before clinical symptoms manifest. By detecting leukocyte accumulation and plaque vulnerability markers in early stages, the system allows for preventive intervention before cardiovascular events occur, significantly improving prevention reliability.
Solution Approach 2:
The molecular imaging approach replaces traditional mechanical diagnostic methods with a chemically-based detection system. This substitution enables early detection of biochemical changes in plaques (inflammation, leukocyte infiltration) that precede structural changes detectable by conventional imaging, allowing earlier intervention.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of DANBIRT enables non-invasive, precise imaging of inflammatory leukocyte presence and accumulation in atherosclerotic plaques, facilitating early detection and monitoring of atherosclerosis, thereby reducing the risk of cardiovascular events.
Implementation Method 1
A novel radioligand, DANBIRT, targeted at leukocyte function-associated antigen-1 (LFA-1), is developed, which can be labeled with radioisotopes like 111In for non-invasive imaging of inflammation and immune cell activity in vascular tissues
Data Source
AI summary
The present invention is directed to novel non-invasive diagnostic took to dispose numerous disease states and/or conditions. The presets invention, represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these disease states. The novel imaging probe is capable of detecting infected cells, as well tissue. The methods described herein are able to diagnose, treat and/or monitor the therapy of numerous diseases and conditions including atherosclerosis, atherothrombosis, cerebral vascular disease, cerebral ischemia, cerebral infarct and meningitis as well as pneumonitis, pericarditis, multiple sclerosis, lupus erythematosus and pancreatitis, among others.